Study to Evaluate the Efficacy and Safety of Elafibranor in Patients With Primary Biliary Cholangitis (PBC) and Inadequate Response to Ursodeoxycholic Acid

NCT03124108 · clinicaltrials.gov ↗

PHASE2

Phase

COMPLETED

Status

45

Enrollment

INDUSTRY

Sponsor class

Conditions

Primary Biliary Cholangitis (PBC)

Interventions

DRUG: Elafibranor 80 mg
DRUG: Elafibranor 120 mg
DRUG: Placebo

Sponsor

Genfit